Analysts predict that Catalyst Biosciences Inc (NASDAQ:CBIO) will post ($1.20) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings per share of ($0.54) during the same quarter last year, which indicates a negative year-over-year growth rate of 122.2%. The firm is expected to announce its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Catalyst Biosciences will report full year earnings of ($4.88) per share for the current financial year. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.18).

Separately, Zacks Investment Research downgraded EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd.

Shares of CBIO stock traded down $0.18 on Friday, reaching $8.27. The company’s stock had a trading volume of 114,175 shares, compared to its average volume of 357,969. The company has a debt-to-equity ratio of 0.02, a current ratio of 24.94 and a quick ratio of 24.94. Catalyst Biosciences has a 12-month low of $6.20 and a 12-month high of $11.44. The firm has a market cap of $99.08 million, a P/E ratio of -3.09 and a beta of 2.19. The company has a 50 day simple moving average of $7.82.

Several large investors have recently made changes to their positions in CBIO. Nantahala Capital Management LLC bought a new stake in shares of Catalyst Biosciences during the 4th quarter valued at $6,748,000. Dimensional Fund Advisors LP lifted its stake in shares of Catalyst Biosciences by 25.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 508,232 shares of the biopharmaceutical company’s stock worth $4,010,000 after buying an additional 103,874 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Catalyst Biosciences by 40.8% in the first quarter. Assenagon Asset Management S.A. now owns 288,600 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 83,701 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Catalyst Biosciences by 1,127.7% in the fourth quarter. Bank of America Corp DE now owns 58,559 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 53,789 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Catalyst Biosciences by 4.8% in the fourth quarter. BlackRock Inc. now owns 846,529 shares of the biopharmaceutical company’s stock worth $6,680,000 after buying an additional 39,088 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Story: What is the Rule of 72?

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.